Ladenburg Thalmann Financial Services’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-197	Closed	-$5K	–	5376
2018 Q2	$5K	Hold	197	–	–	﹤0.01%	4614
2018 Q1	$5K	Sell	197 -68	-26%	-$1.51K	﹤0.01%	4614
2017 Q4	$7K	Buy	+265	New	+$5.34K	﹤0.01%	4401
2017 Q1	–	Sell	-142	Closed	-$1K	–	5007
2016 Q4	$1K	Hold	142	–	–	﹤0.01%	4738
2016 Q3	$1K	Hold	142	–	–	﹤0.01%	4686
2016 Q2	$2K	Sell	142 -7,390	-98%	-$94.1K	﹤0.01%	4455
2016 Q1	$103K	Hold	7,532	–	–	﹤0.01%	2046
2015 Q4	$143K	Sell	7,532 -373	-5%	-$8.11K	﹤0.01%	1808
2015 Q3	$148K	Buy	7,905 +7,195	+1,013%	+$122K	﹤0.01%	1713
2015 Q2	$11K	Buy	+710	New	+$10.8K	﹤0.01%	3644

Other funds holding CNCE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CNCE Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 197 shares — an estimated $5K sold.

Ladenburg Thalmann Financial Services first reported a position in CNCE in Q2 2015 and held it in 10 quarters. The position peaked at $148K in Q3 2015. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

Ladenburg Thalmann Financial Services reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 197 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $5K.
Ladenburg Thalmann Financial Services first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Ladenburg Thalmann Financial Services's Concert Pharmaceuticals, Inc. position peaked at $148K in Q3 2015.
111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.